Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 124637. Отображено 100.
05-01-2012 дата публикации

Method of reducing multi-drug resistance using inositol tripyrophosphate

Номер: US20120003327A1
Автор: Claudine Kieda, Jean-Marie Lehn, Yves Claude Nicolau
Принадлежит: Individual

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Homogenous preparations of il-28 and il-29

Номер: US20120004161A1
Автор: Chung Chan, Dennis L. Dong, Hong Y. Liu, Kevin M. Klucher, Lowell J. Brady, Paul O. Sheppard, Thomas R. Bukowski
Принадлежит: Zymogenetics Inc

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Подробнее
Номер записи: 2
05-01-2012 дата публикации

N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands

Номер: US20120004214A1
Автор: Dan Peters, Daniel B. Timmermann, Eva Dam Christoffersen
Принадлежит: Neurosearch AS

This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Formula (I) a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ar represents an indolyl group, which indolyl may optionally be substituted one or more times with substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkyl, hydroxy and alkoxy.

Подробнее
Номер записи: 3
05-01-2012 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20120004216A1
Автор: Ashvani K. Singh, Lewis R. Makings, Mark T. Miller, Matthew Hamilton, Peter D.J. Grootenhuis, Sara S. Hadida Ruah, Thomas Cleveland
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее
Номер записи: 4
05-01-2012 дата публикации

Organic compounds

Номер: US20120004247A1
Автор: Brian Cox, Robin Alec Fairhurst, Roger John Taylor
Принадлежит: NOVARTIS AG

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

Подробнее
Номер записи: 5
05-01-2012 дата публикации

Compounds for the treatment of pathologies associated with aging and degenerative disorders

Номер: US20120004263A1
Автор: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
Принадлежит: University of Pittsburgh

The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.

Подробнее
Номер записи: 6
05-01-2012 дата публикации

Bile salt adjuvant for animals for improving fat utilization efficiency in the bodies of animals, and animal feed comprising same

Номер: US20120004304A1
Автор: Kwan-Sik Yun
Принадлежит: KIMIN Inc

The present invention relates to a bile salt adjuvant for animals for improving fat utilization efficiency in the bodies of the animals, and to animal feed comprising same. More particularly, the present invention relates to a bile salt adjuvant for animals comprising sodium stearoyl-2-lactylate. The adjuvant is used in animal feed to improve fat utilization efficiency in the bodies of livestock when ingested by said livestock, thereby reducing the amount of fat required to be used in animal feed and improving productivity.

Подробнее
Номер записи: 7
12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1
Автор: Anton Mayr, Barbara Mayr
Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее
Номер записи: 8
12-01-2012 дата публикации

Prebiotic Formulations for use with Probiotics to Increase Probiotic Growth Rate and Activity

Номер: US20120009239A1
Автор: Randolph S. Porubcan, Sonja Lea Yonak
Принадлежит: MASTER SUPPLEMENTS Inc

Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Подробнее
Номер записи: 9
12-01-2012 дата публикации

Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell

Номер: US20120010124A9
Автор: Bertrand Alluis, Jean-Sebastien Fruchart
Принадлежит: Diatos SA

The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.

Подробнее
Номер записи: 10
19-01-2012 дата публикации

Enterically coated cysteamine, cystamine and derivatives thereof

Номер: US20120015038A1
Автор: Jerry Schneider, Ranjan Dohil
Принадлежит: UNIVERSITY OF CALIFORNIA

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Подробнее
Номер записи: 11
19-01-2012 дата публикации

Sulfone Compounds Which Modulate The CB2 Receptor

Номер: US20120015988A1
Автор: Christopher Francis Palmer, David Smith Thomson, Doris Riether, Eugene Richard Hickey, Mark Whittaker, Monika Ermann, Patricia Amouzegh, Renee M. Zindell
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
Номер записи: 12
19-01-2012 дата публикации

Method for Synthesizing Pirfenidone

Номер: US20120016133A1
Автор: Michael Cyr, Ramachandran Radhakrishnan, Sabine M. Pyles
Принадлежит: Intermune Inc

A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.

Подробнее
Номер записи: 13
26-01-2012 дата публикации

MHC-Less cells

Номер: US20120020885A1
Автор: Edward K.Y. Jung, Elizabeth A. Sweeney, Eric C. Leuthardt, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Stephen L. Malaska, Wayne R. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.

Подробнее
Номер записи: 14
26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1
Автор: Curtis Thompson, Gregory I. Frost, Harold Michael Shepard, Xiaoming Li
Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее
Номер записи: 15
26-01-2012 дата публикации

Methods and compositions for liver cancer therapy

Номер: US20120020961A1
Автор: Anne-Sophie Dume, Dominique Joubert, Frédéric HOLLANDE, Leïla Houhou
Принадлежит: Biorealites SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut National de la Sante et de la Recherche Medicale INSERM

The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.

Подробнее
Номер записи: 16
26-01-2012 дата публикации

Garcinia Mangostana L. and Iridoid Based Formulations

Номер: US20120021079A1
Автор: Afa Kehaati Palu, Brett Justin West, Claude Jarakae Jensen, Jeffery A. Wasden, Shixin Deng
Принадлежит: Individual

Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Подробнее
Номер записи: 17
26-01-2012 дата публикации

Combination of an insulin and a glp-1-agonist

Номер: US20120021978A1
Автор: Barbel Rotthauser, Christopher James Smith, Ulrich Werner
Принадлежит: Sanofi Aventis Deutschland GmbH

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

Подробнее
Номер записи: 18
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
Номер записи: 19
26-01-2012 дата публикации

Histamine h3 inverse agonists and antagonists and methods of use thereof

Номер: US20120022050A1
Автор: Kerry L. Spear, Milan Chytil, Qun Kevin Fang, Sharon R. Engel
Принадлежит: SUNOVION PHARMACEUTICALS INC

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Подробнее
Номер записи: 20
26-01-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120022139A1
Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
Номер записи: 21
26-01-2012 дата публикации

Compositions and Methods for Induced Brown Fat Differentiation

Номер: US20120022500A1
Автор: Bruce M. Spiegelman, Shingo Kajimura
Принадлежит: Dana Farber Cancer Institute Inc

The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm1β and C/EBPβ activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm1β and C/EBPβ expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm1β and C/EBPβ expression and/or activity.

Подробнее
Номер записи: 22
02-02-2012 дата публикации

Transdermal pharmaceutical preparations

Номер: US20120024743A1
Автор: Endre Mikulásik, Patrik Fazekas
Принадлежит: EGIS PHARMACEUTICALS PLC

The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.

Подробнее
Номер записи: 23
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
Номер записи: 24
02-02-2012 дата публикации

Methods for treating diabetes

Номер: US20120027729A1
Автор: Darwin J. Prockop, Min Jeong Seo, Ryang Hwa Lee
Принадлежит: Tulane University

Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.

Подробнее
Номер записи: 25
02-02-2012 дата публикации

Method for alleviating intestinal problems and novel bacterial strains therefor

Номер: US20120027734A1
Автор: Benedikt Sas, Filip Van Immerseel, Frank Pasmans, Freddy Haesebrouck, Richard Ducatelle, Venessa Eeckhaut
Принадлежит: Individual

The present invention relates to butyrate producing bacterial strains related to the species Buty{acute over (η)}coccus pullicaecorum to be used in the prevention and/or treatment of intestinal health problems. The present invention therefore provides methods and compositions that overcome the problems associated with the currently used methods for administering butyric acid in the treatment of intestinal health problems in humans and/or animals.

Подробнее
Номер записи: 26
02-02-2012 дата публикации

Methods for treating adult respiratory distress syndrome

Номер: US20120027742A1
Автор: Jahar Bhattacharya, Sadiqa K. Quadri, Shonit Das
Принадлежит: Columbia University of New York

We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.

Подробнее
Номер записи: 27
02-02-2012 дата публикации

Genetically programmable pathogen sense and destroy

Номер: US20120027786A1
Автор: Ron Weiss, Saurabh Gupta
Принадлежит: Massachusetts Institute of Technology

Aspects of the invention relate to compositions and methods for using recombinant cells to sense and destroy specific pathogens.

Подробнее
Номер записи: 28
02-02-2012 дата публикации

Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications

Номер: US20120028922A1
Автор: Fotini Sampalis
Принадлежит: Individual

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Подробнее
Номер записи: 29
02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1
Автор: Christoph Hoenke, Dieter Wolfgang Hamprecht, Domnic Martyres, Peter Seither, Ralf Anderskewitz, Thorsten Oost, Wolfgang Rist
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее
Номер записи: 30
02-02-2012 дата публикации

7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof

Номер: US20120029044A1
Автор: Gwenaella Rescourio, Jurg R. Pfister, Meenakshi S. Venkatraman, Xiaoming Zhang
Принадлежит: Theron Pharmaceuticals Inc

Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.

Подробнее
Номер записи: 31
02-02-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120029052A1
Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
Номер записи: 32
02-02-2012 дата публикации

Compositions for treating or preventing obesity and insulin resistance disorders

Номер: US20120029065A1
Автор: David A. Sinclair, Maria Alexander-Bridges
Принадлежит: General Hospital Corp, Harvard College

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

Подробнее
Номер записи: 33
02-02-2012 дата публикации

Compositions and methods for treating or preventing radiation injury

Номер: US20120029071A1
Автор: Rajesh K. Thimmulappa, Shyam Biswal
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods featuring Nrf2 activators for treating or preventing radiation-associated tissue damage.

Подробнее
Номер записи: 34
09-02-2012 дата публикации

4'-substituted nucleoside derivatives as inhibitors of hcv rna replication

Номер: US20120034184A1
Автор: Christopher John Hobbs, Isabel Najera, John Herbert Merrett, Joseph Armstrong Martin, Nobuo Shimma, Rene Robert Devos, Takuo Tsukuda, Wen Rong Jiang
Принадлежит: Individual

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Подробнее
Номер записи: 35
09-02-2012 дата публикации

Extracellular matrix compositions for tissue regeneration

Номер: US20120034191A1
Автор: Robert G. Matheny
Принадлежит: Individual

The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.

Подробнее
Номер записи: 36
09-02-2012 дата публикации

Treatment of neurotrophic factor mediated disorders

Номер: US20120034193A1
Автор: Antonia Orsi, Daryl Rees, Patrick Howson, Yaer Hu, Zongqin Xia
Принадлежит: Phytopharm Ltd

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Подробнее
Номер записи: 37
09-02-2012 дата публикации

Method of Administering an Antibody

Номер: US20120034243A1
Автор: David Edward Allison, Judith A. Fox, Lee R. Brettman
Принадлежит: Genentech Inc, Millennium Pharmaceuticals Inc

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

Подробнее
Номер записи: 38
09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1
Автор: Alessandro FATATIS, Nathan Graeme DOLLOFF, Nick LOIZOS
Принадлежит: ImClone LLC, Philadelphia Health and Education Corp

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее
Номер записи: 39
09-02-2012 дата публикации

Compositions for the treatment of gluten intolerance and uses thereof

Номер: US20120034299A1
Автор: Hugh James Beatty Cornell, Teodor Stelmasiak
Принадлежит: Glutagen Pty Ltd

The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analogue or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.

Подробнее
Номер записи: 40
09-02-2012 дата публикации

Reduced-cholesterol dairy product for use as a medicament

Номер: US20120034308A1
Автор: Daniel Dalemans
Принадлежит: Corman SA

A ruminant reduced-cholesterol dairy product is used as a medicament.

Подробнее
Номер записи: 41
09-02-2012 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20120035073A1
Автор: Brisdell Hunte, Hilary Clark, Janet K. Jackman, Jill R. Schoenfeld, P. Mickey Williams, Sarah C. Bodary-Winter, Thomas D. Wu, William I. Wood
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
Номер записи: 42
16-02-2012 дата публикации

Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Номер: US20120039936A1
Автор: Paul Howley, Sonja Leyrer
Принадлежит: Individual

The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.

Подробнее
Номер записи: 43
16-02-2012 дата публикации

Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof

Номер: US20120040984A1
Автор: Christophe Philippo, Claudie Namane, Eric Nicolai, Eykmar Fett, Patrick Mougenot
Принадлежит: SANOFI SA

The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.

Подробнее
Номер записи: 44
23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1
Автор: Alexey V. Teplyakov, Ellen Chi, Gopalan Raghunathan, Hong Mimi Zhou, Jill Giles-Komar, Jill M. Carton, Johan Fransson, Juan C. Almagro, Karyn T. O'neil, Linus Hyun, Ronald V. Swanson, Shanrong Zhao, Wendy Cordier, Yiqing Feng
Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее
Номер записи: 45
23-02-2012 дата публикации

Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Номер: US20120045455A1
Автор: Alan D. Robertson, Diego Silva, Ian Alexander McDonald
Принадлежит: PHARMAXIS LTD

Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosis after surgery, glaucoma, tendon scarring disorders, joint scarring disorders, kidney interstitial fibrosis and glomerular fibrosis and tubular fibrosis of the kidney.

Подробнее
Номер записи: 46
23-02-2012 дата публикации

Thermosensitive hepatitis b vaccine

Номер: US20120045511A1
Автор: Ho-Yuan Chou, Hsin-Hsin Shen, Mi-Hua Tao, Tsai-Yu Lin
Принадлежит: Industrial Technology Research Institute ITRI

A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness.

Подробнее
Номер записи: 47
23-02-2012 дата публикации

TNF-alpha Antagonists Containing IGFBP5

Номер: US20120046217A1
Автор: Jae-ho Huh, Jae-Ryoung Hwang, Je-Ho Lee
Принадлежит: Sungkyunkwan University Foundation For Corporate Collaboration

The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.

Подробнее
Номер записи: 48
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Автор: Hiroki Fukudome, Hiroshi Moritani, Takahiro Nigawara, Takeshi Hanazawa, Tomoaki Kawano, Yasuhiro Yonetoku
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
Номер записи: 49
23-02-2012 дата публикации

Compounds for the Treatment of Hepatitis C

Номер: US20120046294A1
Автор: John F. Kadow, Richard Pracitto
Принадлежит: Bristol Myers Squibb Co

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Подробнее
Номер записи: 50
23-02-2012 дата публикации

ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

Номер: US20120046451A1
Автор: Akihiko Takasaki, Atsushi Sugioka, Chiho Muramatsu, Gene Kurosawa, Kazuhiro Morishita, Kazuhiro Suzuki, Kazuki Matsuda, Keiko Ogawa, Mariko Sumitomo, Masachika Azuma, Miwa Morita, Nobuhiro Hayashi, Nobuhiro Takahashi, Sari Fujiyama, Susumu Tsutsumi, Yasushi Akahori, Yoshikazu Kurosawa, Yoshinori Ukai, Yoshitaka Iba
Принадлежит: Institute for Antibodies Co Ltd

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Подробнее
Номер записи: 51
08-03-2012 дата публикации

Modulation of drug release rate from electrospun fibers

Номер: US20120058100A1
Автор: Jay C. Sy, V. Prasad Shastri
Принадлежит: Individual

Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically active agents and/or biologically active agents. Also disclosed are processes of delivering pharmaceutically active agents and/or biologically active agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Подробнее
Номер записи: 52
08-03-2012 дата публикации

Lipid encapsulated interfering rna

Номер: US20120058188A1
Автор: Ellen Grace Ambegia, Ian Maclachlan, James Heyes
Принадлежит: PROTIVA BIOTHERAPEUTICS INC

The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.

Подробнее
Номер записи: 53
08-03-2012 дата публикации

Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved

Номер: US20120058572A1
Автор: Naruto Katsuragi, Ryuichi Morishita, Yoshiaki Taniyama
Принадлежит: Daiichi Sankyo Co Ltd, Osaka University NUC

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

Подробнее
Номер записи: 54
08-03-2012 дата публикации

Nutritional composition inducing a postprandial endocrine response

Номер: US20120058938A1
Автор: Mirian Lansink, Robert Johan Joseph Hageman
Принадлежит: Nutricia NV

The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.

Подробнее
Номер записи: 55
08-03-2012 дата публикации

Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof

Номер: US20120058939A9
Автор: Alan John Henderson, Emily Elizabeth FREEMAN, Mark Hadden, Matthew David Surman, Peter R. GUZZO
Принадлежит: Albany Molecular Research Inc

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

Подробнее
Номер записи: 56
08-03-2012 дата публикации

Feedback prodrug

Номер: US20120058960A1
Автор: Geert-Jan Boons, Jun Guo
Принадлежит: University of Georgia Research Foundation Inc UGARF

Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.

Подробнее
Номер записи: 57
08-03-2012 дата публикации

Di-azetidinyl diamide as monoacylglycerol lipase inhibitors

Номер: US20120058986A1
Автор: Bin Zhu, Mark J. Macielag, Peter J. Connolly
Принадлежит: Janssen Pharmaceutica NV

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

Подробнее
Номер записи: 58
08-03-2012 дата публикации

Novel kinase modulators

Номер: US20120059001A1
Автор: Govindarajulu Babu, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Swaroop Kumar V.S. Vakkalanka
Принадлежит: Incozen Therapeutics Pvt Ltd, Rhizen Pharmaceuticals SA

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Подробнее
Номер записи: 59
15-03-2012 дата публикации

Delivery system with scaffolds

Номер: US20120063997A1
Автор: Cheryl Hunter, Kevin Morris Shakessheff, Robin Andrew Quirk
Принадлежит: REGENTEC Ltd

An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it can be used in tissue regeneration or reconstruction. The agent for delivery may be a therapeutically, prophylactically or diagnostically active substance.

Подробнее
Номер записи: 60
15-03-2012 дата публикации

Peptidomimetic protease inhibitors

Номер: US20120064034A1
Автор: Cristina Garcia-Paredes, Deqi Guo, Frantz Victor, Ivan Collado, Jason Eric Lamar, John Irvin Glass, LING Jin, Luc Farmer, Mark Joseph Tebbe, Nancy June Snyder, Q. May Wang, Raymond Samuel Parker, Iii, Robert B. Perni, Robert Edward Babine, Shu Hui Chen, Xicheng David Sun, Yvonne Yee Mai Yip
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Подробнее
Номер записи: 61
15-03-2012 дата публикации

Monoclonal Antibodies to Hepatocyte Growth Factor

Номер: US20120064066A1
Автор: Kyung Jin Kim, Yi-Chi Su
Принадлежит: Galaxy Biotech LLC

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Подробнее
Номер записи: 62
15-03-2012 дата публикации

Compounds and their uses 708

Номер: US20120065214A1
Автор: Piotr Raubo, Richard Evans, Stephen Brough, Timothy Jon Luker
Принадлежит: AstraZeneca AB

The present invention relates to pyrazinone derivatives of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Подробнее
Номер записи: 63
22-03-2012 дата публикации

Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same

Номер: US20120070504A1
Автор: Joan M. Fallon
Принадлежит: Curemark LLC

A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.

Подробнее
Номер записи: 64
22-03-2012 дата публикации

Pyrazole oxadiazole derivatives as s1p1 agonists

Номер: US20120071460A1
Автор: Anna Quattropani, Charles Baker-Glenn, Chris KNIGHT, Wesley Blackaby
Принадлежит: MERCK SERONO SA

The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R 1 , R 2 and R 3 are as defined in the description.

Подробнее
Номер записи: 65
22-03-2012 дата публикации

Tetrazole Compounds Which Selectively Modulate The CB2 Receptor

Номер: US20120071529A1
Автор: Doris Riether, Monika Ermann, Renee M. Zindell
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
Номер записи: 66
22-03-2012 дата публикации

Estrogen receptor modulators and uses thereof

Номер: US20120071535A1
Автор: Andiliy G. Lai, Celine Bonnefous, Jackaline D. Julien, Johnny Y. Nagasawa, Mehmet Kahraman, Nicholas D. Smith, Steven P. Govek
Принадлежит: Aragon Pharmaceuticals Inc

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Подробнее
Номер записи: 67
29-03-2012 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20120076755A1
Автор: Ce Wang, Hui Cao, LU Ying, Xiaowen Peng, Yao-Ling Qiu, Yat Sun Or
Принадлежит: Enanta Pharmaceuticals Inc

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Подробнее
Номер записи: 68
29-03-2012 дата публикации

Drug carrier and drug carrier kit for inhibiting fibrosis

Номер: US20120076852A1
Автор: Junji Kato, Yasushi Sato, Yoshiro Niitsu
Принадлежит: Nitto Denko Corp

An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Подробнее
Номер записи: 69
29-03-2012 дата публикации

Methods of enhancing drug delivery and effectiveness of therapeutic agents

Номер: US20120076862A1
Автор: Neil P. Desai, Patrick Soon-Shiong
Принадлежит: Individual

The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”). Also provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein.

Подробнее
Номер записи: 70
29-03-2012 дата публикации

Composition with improved bioavailability of saponin and method for improving the bioavailability of saponin (as amended)

Номер: US20120076874A1
Автор: Chan Woong Park, Dae Bang Seo, Hee Young Jeon, Ji Hae Lee, Kyung Mi Joo, Kyung Min Lim, Sang Jun Lee
Принадлежит: Amorepacific Corp

The present invention relates to a ginseng mixed composition with improved bioavailability of saponin. Further, the present invention relates to a method for improving saponin bioavailability of a subject comprising: administering to the subject an effective amount of at least one extract selected from a Schizandra chinensis extract and a Liriope platyphylla extract that improves saponin bioavailability in the subject.

Подробнее
Номер записи: 71
29-03-2012 дата публикации

Prophylactic agent for renal failure

Номер: US20120077735A1
Автор: Kohji Ohki, Tatsuhiko Hirota, Teppei Nakamura, Toshiaki Takano
Принадлежит: Individual

The present invention provides an agent having a suppressive action against kidney glomerular disease and renal arteriosclerosis, a prophylactic agent for renal failure containing the above described agent, and functional foods expected to have a prophylactic effect for renal failure. The agent for preventing kidney glomerular disease and renal arteriosclerosis comprises Xaa Pro Pro as an active ingredient.

Подробнее
Номер записи: 72
29-03-2012 дата публикации

Pharmaceutical product

Номер: US20120077856A1
Автор: Masayuki Ii, Tomohiro Kawamoto, Yuji Iizawa
Принадлежит: Takeda Pharmaceutical Co Ltd

An agent for suppressing the production of various cytokines (IL-8 and the like) and inflammatory mediators, an agent for suppressing the expression of COX-II and the like, or an inhibitor of various phosphorylation enzymes (ATF2 and the like), which contains a TLR signaling inhibitory substance, preferably a compound represented by the formula (I) or the formula (II) wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

Подробнее
Номер записи: 73
05-04-2012 дата публикации

Soluble il-17ra/rc fusion proteins and related methods

Номер: US20120082668A1
Автор: Gao Zeren, Mark W. Rixon, Steven D. Levin
Принадлежит: Zymogenetics Inc

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Подробнее
Номер записи: 74
05-04-2012 дата публикации

Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors

Номер: US20120083494A1
Автор: Anne-Laure Blayo, Babette Aicher, Gilbert Mueller, Jean Martinez, Jean-Alain Fehrentz, Klaus Paulini, Lars Blumenstein, Matthias Gerlach, Michael Teifel, Peter Schmidt
Принадлежит: Aeterna Zentaris GmbH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Universite de Montpellier I, Universite de Montpellier II

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Подробнее
Номер записи: 75
12-04-2012 дата публикации

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Номер: US20120088746A1
Автор: Hirotaka Tanaka, John Kincaid, Kazunari Nakao, Kiran Sahasrabudhe, Maria de los Ángeles ESTIARTE-MARTÍNEZ, Matthew Alexander James Duncton, Matthew Cox, Satoshi Nagayama, Yuji Shishido
Принадлежит: PFIZER INC

Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Подробнее
Номер записи: 76
12-04-2012 дата публикации

Compounds for enzyme inhibition

Номер: US20120088762A1
Автор: Catherine Sylvain, Francesco Parlati, Guy J. Laidig, Han-Jie Zhou, Kevin D. Shenk, Mark K. Bennett, Mark S. Smyth
Принадлежит: Onyx Therapeutics Inc

One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.

Подробнее
Номер записи: 77
19-04-2012 дата публикации

Mangiferin-Berberine Salt, Manufacturing Method and Use Thereof

Номер: US20120094941A1
Автор: Houlei Teng, Wei Wu
Принадлежит: Hainan Deze Drug Research Co Ltd

The present invention provides a mangiferin-berberine salt and manufacturing method thereof. Otherwise, the present invention also provides the use of mangiferin-berberine salt as AMPK activator.

Подробнее
Номер записи: 78
19-04-2012 дата публикации

Egfr inhibitors and methods of treating disorders

Номер: US20120094999A1
Автор: Michael J. Eck, Nathanael S. Gray, Pasi Janne, Wenjun Zhou
Принадлежит: Dana Farber Cancer Institute Inc

The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Подробнее
Номер записи: 79
26-04-2012 дата публикации

Humanized antibodies against light and uses thereof

Номер: US20120100074A1
Автор: Bridget A. Cooksey, Craig Rosen, Palanisamy Kanakaraj, Rodger Smith, Viktor Roschke
Принадлежит: Teva Biopharmaceuticals USA Inc

The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).

Подробнее
Номер записи: 80
26-04-2012 дата публикации

Regionalised endoderm cells and uses thereof

Номер: US20120100115A1
Автор: Gillian Mary Morrison, Ifigenia Oikonomopoulou, Joshua Mark Brickman
Принадлежит: University of Edinburgh

The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cells markers and the like and their potential uses in a variety of applications.

Подробнее
Номер записи: 81
26-04-2012 дата публикации

Stable pharmaceutical composition and methods of using same

Номер: US20120100208A1
Автор: Mehar Manku
Принадлежит: Amarin Pharma Inc

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 82
26-04-2012 дата публикации

Pharmaceutical formulations of a substituted diaminopurine

Номер: US20120100213A1
Автор: Anthony Joseph FRANK, Anthony Tutino, Sreenivas S. Bhat, Xiaozhong Liang
Принадлежит: Signal Pharmaceuticals LLC

Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.

Подробнее
Номер записи: 83
26-04-2012 дата публикации

Antibodies having altered effector function and methods for making the same

Номер: US20120100575A1
Автор: Ellen Garber, Frederick R. Taylor
Принадлежит: BIOGEN IDEC MA INC

The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Подробнее
Номер записи: 84
03-05-2012 дата публикации

Use of LCAT for Treating Anemia and Red Blood Cell Dysfunction

Номер: US20120107298A1
Автор: Brian Krause, Bruce J. Auerbach, Reynold Homan
Принадлежит: Alphacore Pharma LLC

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.

Подробнее
Номер записи: 85
03-05-2012 дата публикации

Composition for treatment of menopause

Номер: US20120107344A1
Автор: Isaac Cohen
Принадлежит: Bionovo Inc

A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause.

Подробнее
Номер записи: 86
03-05-2012 дата публикации

Compounds and compositions for treating chemical warfare agent-induced injuries

Номер: US20120108613A1
Автор: Jayhong A. Chong
Принадлежит: Hydra Biosciences LLC

Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.

Подробнее
Номер записи: 87
03-05-2012 дата публикации

N1/n2-lactam acetyl-coa carboxylase inhibitors

Номер: US20120108619A1
Автор: Aaron Smith, David A. Griffith, Robert L. Dow, Scott W. Bagley
Принадлежит: PFIZER INC

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Подробнее
Номер записи: 88
03-05-2012 дата публикации

Nitrogen-containing aromatic heterocyclyl compound

Номер: US20120108639A1
Автор: Akihiro Tamura, Keiko Suzuki, Mitsuhiro Yamaguchi, Takahiro Yamaguchi, Tomohiro Nishizawa
Принадлежит: Daiichi Sankyo Co Ltd

The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R 1 represents COOH; each R 2 represents an alkyl; each R 3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R 4 , R 5 , R 6 , and R 7 represents H, an alkyl; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B 1 and B 2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.

Подробнее
Номер записи: 89
10-05-2012 дата публикации

Tslp promotes immune evasion and persistence of viruses

Номер: US20120114596A1
Автор: Bernhard Homey, Isabel Fernandez, Vassili Soumelis
Принадлежит: HEINRICH-HEINE-UNIVERSITAET, INSTITUT CURIE, Institut National de la Sante et de la Recherche Medicale INSERM

It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.

Подробнее
Номер записи: 90
10-05-2012 дата публикации

Novel inhibitors of hepatitis c virus

Номер: US20120114600A1
Автор: Daisuke Roland Saito, Daniel D. Long, Eric L. Stangeland, Gavin Ogawa, Kassandra Lepack, Lan Jiang, Lori Jean Van Orden, Mandy Loo, Robert Murray Mckinnell, Shella ZIPFEL
Принадлежит: Theravance Inc

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Подробнее
Номер записи: 91
10-05-2012 дата публикации

Compositions and methods for inhibiting viral and/or bacterial infections

Номер: US20120114639A1
Автор: Michelle Adair Ozbun, Zurab Surviladze
Принадлежит: STC UNM

We describe herein compositions and methods related to inferring with microbial infection. Generally, the compositions include an infection antagonist that inhibits formation of a heparin sulfonated proteoglycan (HSPG)-containing infection complex. Generally, the methods include administering to a subject an amount of a composition as described herein effective to inhibit infection by a microorganism that that infects a host through interactions that involve HSPG.

Подробнее
Номер записи: 92
10-05-2012 дата публикации

Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof

Номер: US20120114742A1
Автор: Alexa L. Martinez, L. David Williams, Mark G.P. Saifer, Merry R. Sherman
Принадлежит: Mountain View Pharmaceuticals Inc

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

Подробнее
Номер записи: 93
10-05-2012 дата публикации

Pharmaceutical composition for treating hcv infections

Номер: US20120114751A1
Автор: Andreas Leiminer, Dave Alan Miller, Emmanuel Scheubel, Kai Lindenstruth, Navnit Hargovindas Shah
Принадлежит: Hoffmann La Roche Inc

The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer.

Подробнее
Номер записи: 94
10-05-2012 дата публикации

TGR5 Modulators and Methods of Use Thereof

Номер: US20120115832A1
Автор: Roberto Pellicciari
Принадлежит: Intercept Pharmaceuticals Inc

The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.

Подробнее
Номер записи: 95
10-05-2012 дата публикации

Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders

Номер: US20120115931A1
Автор: Ariane Mallat, Fatima Teixeira Clerc, Jeanne Tran-Van-Nhieu, Sophie Lotersztajn, Sylvie Manin, Vanessa Deveaux
Принадлежит: Individual

The invention relates to a method for treating and/or preventing obesity and/or obesity-related disorders by administering to a subject in need thereof a selective inhibitor of cannabinoid type 2 (CB2) receptor expression.

Подробнее
Номер записи: 96
10-05-2012 дата публикации

Rifaximin

Номер: US20120116071A1
Автор: Dharmaraj Ramachandra Rao, Manjinder Singh Phull, Maruti Ghagare, Rajendra Narayanrao Kankan
Принадлежит: Cipla Ltd

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Подробнее
Номер записи: 97
10-05-2012 дата публикации

Human antibodies derived from immunized xenomice

Номер: US20120117669A1
Автор: Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Raju Kucherlapati, Sue Klapholz
Принадлежит: Abgenix Inc

Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.

Подробнее
Номер записи: 98
17-05-2012 дата публикации

Dry whole milk preparations containing probiotic micro-organisms

Номер: US20120121561A1
Автор: Annick Mercenier, Guénolée Prioult, Sophie Nutten
Принадлежит: Nestec SA

The present invention relates to the field of nutrition for young children. In particular, the present invention relates to dry whole milk preparations comprising probiotic micro-organisms to be administered to young children older than 12 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Подробнее
Номер записи: 99
17-05-2012 дата публикации

Small interfering rna delivery

Номер: US20120121689A1
Автор: Andrew David Bacon, Gregory Gregoriadis, Peter Laing
Принадлежит: Lipoxen Technologies Ltd

A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome size.

Подробнее
Номер записи: 100